Approach to the Patient With Prolactinoma.
Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R.
J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174.
Pituitary apoplexy: managing the life-threatening condition associated with pituitary adenomas.
Witek P.
Minerva Endocrinol. 2014 Dec;39(4):245-59. Epub 2014 Jul 29.
Antigestogens.
Baird DT.
Br Med Bull. 1993 Jan;49(1):73-87. doi: 10.1093/oxfordjournals.bmb.a072607.
Norethynodrel.
[No authors listed]
IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:461-77.
Multiple Endocrine Neoplasia Type 1.
Giusti F, Marini F, Brandi ML.
2005 Aug 31 [updated 2022 Mar 10]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
[Prolactinoma].
Glezer A, Bronstein MD.
Arq Bras Endocrinol Metabol. 2014 Mar;58(2):118-23. doi: 10.1590/0004-2730000002961.
Pituitary tumor apoplexy associated with extrapontine myelinolysis during pregnancy: A case report.
Ye W, Huang W, Chen L, Yao C, Sheng S, Liu Z, Xue C, Xing W.
Medicine (Baltimore). 2021 Mar 12;100(10):e25075. doi: 10.1097/MD.0000000000025075.
Ethynodiol diacetate.
[No authors listed]
IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:387-98.
Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas.
Koizumi K, Aono T.
Fertil Steril. 1986 Aug;46(2):312-4. doi: 10.1016/s0015-0282(16)49531-2.
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Burman P, Abreu AP, Heaney AP, van Hulsteijn L, Lin AL, Marcus H, McCormack A, Minniti G, Petersenn S, Popovic V, Theodoropoulou M, Trouillas J, Dekkers OM.
Eur J Endocrinol. 2025 May 30;192(6):R45-R78. doi: 10.1093/ejendo/lvaf100.
